Overview

Rociletinib (CO-1686) USA Expanded Access Program

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).

Details

Lead Sponsor:

Clovis Oncology, Inc.